19:50 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.
Piramal Pharma Ltd
- Share price
- ₹202.67
- Market cap
- ₹26,982 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -86.0×Sector 47.4×
- Promoter holding
- 34.80%-0.06% QoQ
- FII holding
- 12.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Business Update 7Other Announcement 5Financial Results 3Share Pledge 2Results Update 2Regulatory Approval 2Merger & Restructuring 2Employee Stock Options 2Annual General Meeting 2Management Change 1Earnings Call 1Board Meeting Date 1Adverse Business Impact 1
Time
7 announcements with these filters
17:01 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma Limited released its Sustainability Report for FY2025-26, detailing the company's ESG performance across key pillars, including business resilience and operational sustainability.
17:29 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma has resumed operations at its Ahmedabad facility following the recent temporary suspension due to heavy rainfall. Operations are substantially restored with no material financial impact.
16:37 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma filed its BRSR for FY 2025-26, detailing operations, employees, and subsidiaries. The report is a routine compliance disclosure with no new financial or operational event.
10:59 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma received permanent revocation of closure directions for its Dahej site from GPCB. Operations continue normally, ensuring sustained manufacturing stability and environmental compliance.
11:33 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma received an Establishment Inspection Report from the US FDA for its Telangana facility. The inspection is successfully closed, ensuring regulatory compliance and operational continuity.
22:21 IST
BSE
Business Update
Piramal Pharma Business Update
US FDA concluded inspection of Piramal Pharma's Sellersville facility with three observations. Inspectors recommended VAI classification, with no findings relating to data integrity.